div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: · drug majors Cipla Ranbaxy Lab Hetero Drugs Natco Pharma and others on an appeal filed by Swiss firm Novartis challenging the denial of Patent for Glivec its blood cancer src=https:reader030vdocumentssitereader030viewer20220409185e93289267390c7c8267af48html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: · drug majors Cipla Ranbaxy Lab Hetero Drugs Natco Pharma and others on an appeal filed by Swiss firm Novartis challenging the denial of Patent for Glivec its blood cancer src=https:reader030vdocumentssitereader030viewer20220409185e93289267390c7c8267af48html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: · drug majors Cipla Ranbaxy Lab Hetero Drugs Natco Pharma and others on an appeal filed by Swiss firm Novartis challenging the denial of Patent for Glivec its blood cancer src=https:reader030vdocumentssitereader030viewer20220409185e93289267390c7c8267af48html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 4button div class=ts-image amp-img class=ts-thumb alt=Page 4: · drug majors Cipla Ranbaxy Lab Hetero Drugs Natco Pharma and others on an appeal filed by Swiss firm Novartis challenging the denial of Patent for Glivec its blood cancer src=https:reader030vdocumentssitereader030viewer20220409185e93289267390c7c8267af48html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 5button div class=ts-image amp-img class=ts-thumb alt=Page 5: · drug majors Cipla Ranbaxy Lab Hetero Drugs Natco Pharma and others on an appeal filed by Swiss firm Novartis challenging the denial of Patent for Glivec its blood cancer src=https:reader030vdocumentssitereader030viewer20220409185e93289267390c7c8267af48html5thumbnails5jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 6button div class=ts-image amp-img class=ts-thumb alt=Page 6: · drug majors Cipla Ranbaxy Lab Hetero Drugs Natco Pharma and others on an appeal filed by Swiss firm Novartis challenging the denial of Patent for Glivec its blood cancer src=https:reader030vdocumentssitereader030viewer20220409185e93289267390c7c8267af48html5thumbnails6jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 7button div class=ts-image amp-img class=ts-thumb alt=Page 7: · drug majors Cipla Ranbaxy Lab Hetero Drugs Natco Pharma and others on an appeal filed by Swiss firm Novartis challenging the denial of Patent for Glivec its blood cancer src=https:reader030vdocumentssitereader030viewer20220409185e93289267390c7c8267af48html5thumbnails7jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 8button div class=ts-image amp-img class=ts-thumb alt=Page 8: · drug majors Cipla Ranbaxy Lab Hetero Drugs Natco Pharma and others on an appeal filed by Swiss firm Novartis challenging the denial of Patent for Glivec its blood cancer src=https:reader030vdocumentssitereader030viewer20220409185e93289267390c7c8267af48html5thumbnails8jpg width=142 height=106 layout=responsive amp-img divdiv